ARDX vs DVA
ARDX: Ardelyx commercializes tenapanor-based therapies (IBSRELA for IBS-C, XPHOZAH for kidney disease hyperphosphatemia) with a pipeline of next-generation NHE3 inhibitors. DVA: Leading US dialysis and integrated kidney care provider serving end-stage renal disease patients across clinical centers, home-based settings, and transplant support globally.
Side-by-side fundamentals
| Metric | ARDX | DVA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $5.06 | $236.31 | |
| Market cap as of 2026-07-31 | $1.2B | $15.4B | |
| P/E as of 2026-07-31 | n/a | 19.65 | |
| PEG as of 2026-07-31 | -4.25 | 7.41 | ARDX lower |
| Net margin as of 2026-07-31 | -13.6% | +5.7% | DVA higher |
| Gross margin as of 2026-07-31 | +92.5% | +32.5% | ARDX higher |
| Operating margin as of 2026-07-31 | -8.8% | +15.0% | DVA higher |
| ROE as of 2026-07-31 | -38.1% | +181.2% | DVA higher |
| ROA as of 2026-07-31 | -11.8% | +4.5% | DVA higher |
| Debt / equity as of 2026-07-31 | 1.37 | 77.99 | ARDX lower |
| Revenue growth (YoY) as of 2026-07-31 | +18.2% | +6.7% | ARDX higher |
| Revenue CAGR (3y) SEC XBRL | +98.4% | +5.5% | ARDX higher |
| Beta as of 2026-07-31 | 0.70 | 0.86 | |
| 1-year return as of 2026-07-27 close | +17.9% | +62.8% | DVA higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.